Back to Market返回行情

SNWV SANUWAVE Health, Inc.

USHealthcare
$11.27-6.86%OpenMarket Cap: $96.9M

As of 2026-07-10 13:24

Why SNWV matters now

SANUWAVE Health, Inc. (SNWV) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.27 with -6.86% on the session and $96.9M in market capitalization; recent performance reads 1-month -44.82% and YTD -69.14%.

The latest financial table shown here is Q1 2026, with revenue of $9.6M, net income of $-1.4M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E 12.04 and FCF yield 7.4%.

The latest indexable market news headline is "Sanuwave Health Updates Second Quarter 2026 Guidance" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $54.00; recent insider activity includes Opaleye Management Inc. filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

12.04

PEG

0.09

P/B

43.05

P/S

1.79

EV/EBITDA

4.00

DCF Value

$-35.64

FCF Yield

7.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

75.7%

Operating Margin

6.4%

Net Margin

36.2%

ROE

-450.6%

ROA

43.3%

ROIC

11.4%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$9.6M$-1.4M$-0.17
Q4 2025$13.1M$6.1M$0.02
FY 2025$44.1M$11.8M$0.41
Q3 2025$11.5M$10.3M$1.13

Analyst Ratings

Consensus

Buy

Target (Consensus)

$54.00

Target (Median)

$54.00

Target Range

$53.00 - $55.00

Strong Buy: 0Buy: 1Hold: 0Sell: 0Strong Sell: 0
Roth CapitalBuy
2026-03-30
Roth CapitalBuy
2025-08-22

Trading Activity

Insider Trades

Opaleye Management Inc.10 percent owner
Sell2026-05-04
Opaleye Management Inc.10 percent owner
Sell2026-05-04
Opaleye Management Inc.10 percent owner
Sell2026-05-04
Opaleye Management Inc.10 percent owner
Sell2026-05-04
Opaleye Management Inc.10 percent owner
Sell2026-04-30

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.34

SANUWAVE Health, Inc. is a company dedicated to the research, development, and commercialization of non-invasive, high-energy acoustic shockwave technology. Operating both domestically and internationally, the firm applies these shockwaves in regenerative medicine and other therapeutic areas. The underlying principle involves stimulating a biological response within the body, prompting self-healing through the restoration and growth of tissues, musculoskeletal structures, and vascular networks. Its flagship regenerative product is the dermaPACE device, specifically engineered for treating diabetic foot ulcers. The company's diverse range of healthcare solutions and pipeline products are designed to trigger vital biologic signaling and angiogenic responses, such as fostering new vascularization and improving microcirculation, ultimately revitalizing the body's natural healing and regenerative capabilities. SANUWAVE also utilizes its proprietary Pulsed Acoustic Cellular Expression (PACE) technology across various medical fields, including wound healing, orthopedics, plastic/cosmetic applications, and cardiac conditions. Beyond its core shockwave offerings, the company provides the UltraMIST device, a non-contact, non-thermal ultrasound therapy for managing conditions like diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. Additionally, its orthoPACE system addresses tendinopathies and both acute and nonunion fractures. Established in 2005, SANUWAVE Health, Inc. is based in Suwanee, Georgia.